Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaEssentia Completes Enrollment for Phase 2b and Phase 3 Trials in Blood Disorders
Details : BESREMi (ropeginterferon alfa-2b-njft) targets IFNAR to initiate downstream signaling through the activation of JAK1 and TYK2 and STAT proteins. It is being investigated for essential thrombocythemia.
Brand Name : Besremi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 25, 2024
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Pint Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, i...
Brand Name : Besremi
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 02, 2023
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Pint Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is indicated for the polycythemia vera.
Brand Name : BESREMi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 23, 2023
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is being investigated for polycythemia vera.
Brand Name : BESREMi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 03, 2023
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Undisclosed
Deal Size : $462.7 million
Deal Type : Public Offering
Details : The net proceeds from the offering will be used to to support growth plans and pipeline development, including Besremi (ropeginterferon alfa-2b-njft), an innovative monopegylated, long-acting interferon for the treatment of polycythemia vera (PV) in adul...
Brand Name : Besremi
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 21, 2023
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Undisclosed
Deal Size : $462.7 million
Deal Type : Public Offering
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.
Brand Name : BESREMi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 23, 2023
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.
Brand Name : BESREMi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 02, 2023
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon. It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi is designed to be self-administered subcutaneously...
Brand Name : Besremi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 13, 2022
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (ropeginterferon alfa-2b-njft), is an innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks.
Brand Name : Besremi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 12, 2022
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : P1101 (ropeginterferon alfa-2b-njft) is unique monopegylated, long-acting interferon to treat adults with polycythemia vera. Given well-established safety and efficacy profile demonstrated in prior studies, treatment may represent useful alternative to a...
Brand Name : P1101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 08, 2022
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?